[4]. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (2023 Version 4)[internet]; 2023
[4]Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016 Oct 15;22(20):5097-5108. [5]NCCN Guidelines Version 3.2023 Bre...
NCCN: Breast cancerCarlson RW; Edge SB; Theriault RL; NCCN Breast Cancer Practice Guidelines PanelCancer ControlCancer control : journal of the Moffitt Cancer Center
William J. Gradishar, MD, provides an overview of the current breast cancer treatment landscape, highlights updates to the NCCN guidelines from 2023 to 2024, and expresses optimism for addressing unmet needs at ASCO 2024. This is a modal window. The Playback API request failed for an ...
7.National Comprehensive Cancer Network. Breast Cancer (Version 6.2024). Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419 声明:本材料由阿斯利康支持,仅供医药卫生专业人士参考 审批编号:CN-147056 过期时间:2025-11-17 ...
9.Chen Z, et al. Is HER2 ultra‑low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Res Treat. 2023 Nov;202(2):313-323. 10.National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines...
9. Chen Z, et al. Is HER2 ultra‑low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Res Treat. 2023 Nov;202(2):313-323. 10. National Comprehensive Cance...
Long-Term Pertuzumab Outcomes in HER2+ Breast Cancer: Insights from APHINITY 8-Year Data and NeoSphere Pooled Analysis Risk Stratification and Treatment Selection in HER2+ Breast Cancer: The Current Treatment Landscape and NCCN Guideline Recommendations Future of TROP2- and HER2-Directed ADCs in Brea...
[2] ESMO Metastatic Breast Cancer Living Guidelines, v1.1 May 2023. Ann Oncol 2021;32(12): 1475-1495 [3] ASCO 2024. Abstract # LBA1001. [4] 中国抗癌协会国际医疗与交流分会, 等. 中华肿瘤杂志,2022,44(12):1288-...
[6] Xu B, et al. Int J Cancer. 2023;152(10):2134-2144. [7] National Comprehensive Cancer Network. Breast Cancer (Version 1.2024). [8] Tarantino P, et al. Annals of Oncology, 2023, 34(8): 645-659. [9] ESMO M...